Top Markets
#1 ADO Protocol ADO Protocol +329.37%
#2 GoPlus Security GoPlus Security +53.93%
#3 Verus Coin Verus Coin +43.47%
#4 Nockchain Nockchain +40.54%
#5 The Black Bull The Black Bull +39.50%
#6 Starpower Starpower +35.61%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +34.02%
#8 Tutorial Tutorial +27.75%
#9 Fake World Assets Fake World Assets +24.98%
#10 GAIB AID GAIB AID +24.67%
Coin of the day
ADO Protocol ADO Protocol
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
NuCana plc NuCana plc

NuCana plc

NCNA
Clasificación en acciones #32729
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering... NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
Precio por acción
$1.53
Capitalización bursátil
$9.29M
Cambio (1 día)
-3.77%
Cambio (1 año)
-58.98%
País
GB
Comercio NuCana plc (NCNA)

Categoría

Healthcare
Historial de desdoblamientos de acciones de NuCana plc (NCNA)
La acción NuCana plc (símbolo: NCNA) tuvo un total de 0 desdoblamientos.
El desdoblamiento más reciente ocurrió el Aug 17, 2026.
Una acción NCNA comprada antes de Aug 17, 2026 equivaldría hoy a 0 acciones NCNA.
Lista de desdoblamientos de acciones
Año Desdoblamiento Multiplicador Multiplicador acumulado
Not enough data for the provided dates.
Desdoblamientos de acciones de empresas similares o competidoras
Empresa Número de desdoblamientos de acciones Multiplicador acumulado País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 0 -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 0 -
BE